Chemocentryx

ChemoCentryxis a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx focuses on the discovery, development, and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. The company's small molecule product candidates are designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-- Avacopan demonstrates statistically significant dose-dependent improvement in HiSCR (Hidradenitis Suppurativa Clinical Response) vs. placebo in pre-specified Hurley Stage III (severe HS) patients at 12 weeks; numerical improvement observed with avacopan treatment in overall study population -- -- Consistent reduction in Hurley Stage III patients in International HS Severity Score (IHS4), as well as reduction in AN (abscesses and inflammatory nodules), draining fistula, and abscess count at week 12 --

ChemoCentryx Announces Positive Topline Results of Phase II AURORA Clinical Trial of Avacopan in the Treatment of Hidradenitis Suppurativa (HS)

Adaptimmune Therapeutics

Kodiak Sciences Inc

Seres Therapeutics

Myovant Sciences

Novavax

Sorrento Therapeutics Inc

The pandemic has raised awareness about the value of biotech across the world. In turn, these biotech stocks will benefit down the road.

7 ‘A-Rated’ Aggressive Biotech Stocks to Gamble On

The FDA accepts ChemoCentryx's (CCXI) NDA for avacopan, for the treatment of ANCA-associated vasculitis.

ChemoCentryx's NDA for Autoimmune Disease Drug Accepted by FDA

-- FDA sets PDUFA goal date of July 7, 2021 -- MOUNTAIN VIEW, Calif., Sept.  17, 2020  (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for avacopan, an orally-administered selective complement 5a receptor inhibitor, for the treatment of ANCA-Associated Vasculitis and has set July 7, 2021 as the Prescription Drug User Fee Act (PDUFA) goal date for the avacopan NDA. Avacopan is a first-in-class, orally administered therapy that employs a novel, highly targeted mode of action in the treatment of ANCA-associated vasculitis.

ChemoCentryx Announces FDA Acceptance of the Avacopan New Drug Application (NDA) for the Treatment of ANCA-Associated Vasculitis

MOUNTAIN VIEW, Calif., Sept.  08, 2020  (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 1:30 p.m. ET.

ChemoCentryx to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q2 2020 Results - Earnings Call Transcript

ChemoCentryx (CCXI) delivered earnings and revenue surprises of 185.29% and 494.95%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

ChemoCentryx (CCXI) Q2 Earnings and Revenues Surpass Estimates

-- U.S. New Drug Application (NDA) submitted for avacopan in ANCA-associated vasculitis --   -- Balance sheet bolstered with $325.7 million in net proceeds from June follow-on offering; total cash, cash equivalents and investments greater than $500 million at end of Q2 --

ChemoCentryx Reports Second Quarter 2020 Financial Results and Recent Highlights

MOUNTAIN VIEW, Calif., Aug.  03, 2020  (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2020 financial results will be released after market close on Monday, August 10, 2020. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 10, 2020 to discuss these results and to answer questions.

ChemoCentryx to Hold Second Quarter 2020 Financial Results Conference Call on Monday, August 10, 2020

ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: ChemoCentryx (CCXI) Q2 Earnings Expected to Decline

MOUNTAIN VIEW, Calif., July  09, 2020  (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) today confirmed that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for avacopan for the treatment of patients with ANCA-associated vasculitis.

ChemoCentryx Submits New Drug Application to the U.S. FDA for Avacopan in ANCA-Associated Vasculitis

-- Study to be presented at American Association for Cancer Research (AACR) meeting showed the Company’s orally administered small molecule checkpoint inhibitors led to marked inhibition of PD-1/PD-L1 interaction and signaling in vitro and potent anti-tumor effects in animal models -- -- Study to be presented at American Association for Cancer Research (AACR) meeting showed the Company’s orally administered small molecule checkpoint inhibitors led to marked inhibition of PD-1/PD-L1 interaction and signaling in vitro and potent anti-tumor effects in animal models --

ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatment

MOUNTAIN VIEW, Calif., June  15, 2020  (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq: CCXI) announced today the completion of its follow-on offering of 5,200,000 shares of its common stock. ChemoCentryx also announced today that the underwriters of its follow-on offering exercised in full their option to purchase an additional 780,000 shares of common stock. All such shares were sold by ChemoCentryx at the follow-on public offering price of $58.00 per share. The net proceeds to ChemoCentryx from this offering are approximately $325.4 million, after deducting underwriting discounts and commissions and estimated offering costs.

ChemoCentryx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

MOUNTAIN VIEW, Calif., June  10, 2020  (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has priced an underwritten public offering of 5,200,000 shares of its common stock at a price to the public of $58.00 per share. The gross proceeds to ChemoCentryx from the offering, before underwriting discounts and commissions and offering costs, are expected to be $301,600,000. ChemoCentryx has granted the underwriters a 30-day option to purchase up to an additional 780,000 shares of its common stock on the same terms and conditions. All shares of the common stock to be sold in the offering will be offered by ChemoCentryx. The offering is expected to close on June 15, 2020, subject to satisfaction of customary closing conditions.

ChemoCentryx Prices Public Offering of Common Stock

MOUNTAIN VIEW, Calif., June  10, 2020  (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has commenced an underwritten public offering of its common stock.  In connection with this offering, ChemoCentryx plans to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of shares sold.  SVB Leerink and Piper Sandler are acting as joint bookrunning managers for the offering. All shares of the common stock to be sold in the offering will be offered by ChemoCentryx.  The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

ChemoCentryx Announces Proposed Public Offering of Common Stock

ChemoCentryx: Avacopan's Attractive Value Proposition

MOUNTAIN VIEW, Calif. and ST GALLEN, CH, May  18, 2020  (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced topline data from a forty-six (46) patient Phase II dose-ranging trial in the orphan kidney disorder, primary Focal Segmental Glomerulosclerosis (FSGS). The LUMINA-1 trial tested CCX140, an orally-administered selective inhibitor of the chemokine receptor known as CCR2, in primary FSGS subjects. In the study, CCX140 did not demonstrate a meaningful reduction in proteinuria relative to the control group after 12 weeks of blinded treatment.

ChemoCentryx and VFMCRP Announce Topline Data from Phase II LUMINA-1 Trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)

ChemoCentryx, Inc. (CCXI) CEO Dr.

Does ChemoCentryx (CCXI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Momentum Investors Will Love ChemoCentryx (CCXI)

ChemoCentryx (CCXI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

ChemoCentryx (CCXI) Upgraded to Buy: What Does It Mean for the Stock?

Axsome Therapeutics

DexCom

Eidos Therapeutics Inc

Enphase Energy

According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned stocks have outperformed the S&P 500 Index over the past 12 months as of March 31.

5 Guru Stocks That Beat the Market

Arcturus Therapeutics

Aurinia Pharmaceuticals

Kadmon Hlds

Nevro

Thermo Fisher Scientific

Wall Street pros recommend making an investment decision based on multiple factors rather than just a single metric like fundamentals.

7 “Perfect 10” Healthcare Stocks to Buy Now

ChemoCentryx (CCXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

Why ChemoCentryx (CCXI) Stock Might be a Great Pick

ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q4 2019 Results - Earnings Call Transcript

ChemoCentryx (CCXI) delivered earnings and revenue surprises of 3.70% and 6.70%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

News for Chemocentryx Stock (CCXI)